• CKD epidemic: Global prevalence and economic burden set to surge by 2027 unless action is taken, Inside CKD studies reveal

    In partnership with AstraZeneca, HealthLumen has recently published two publications that project the clinical (1) and economic (2) burden of Chronic Kidney Disease (CKD) and Kidney Replacement Therapy (KRT) into the future, as part of the “Inside CKD” programme, which contributes to the major strategic initiative at AstraZeneca dedicated to driving better patient outcomes. From […]

  • World Kidney Day 2024: Kidney health for all

    It is estimated that a staggering 1 in 10 people worldwide are living with kidney disease (1). Despite its high global prevalence and mortality, CKD has surprisingly often been overlooked on health agendas across the globe up until now. In particular, low and middle-income countries are disproportionately affected by CKD and kidney failure, with a […]

  • The future burden of chronic kidney disease (CKD): how we have climbed “INSIDE CKD” with AstraZeneca using microsimulation-based computer modelling to help improve health outcomes

    HealthLumen, in conjunction with AstraZeneca, have recently published a body of research from the “INSIDE CKD” programme, part of a major strategic initiative at AstraZeneca which is dedicated to changing the future for CKD patients. Our role is to support evidence-based policy making in CKD, which we do by harnessing the predictive power of microsimulation, […]

  • NEWS: Estimating the burden of CKD in the UK

    This week HealthLumen in partnership with AstraZeneca presented new work on the burden of chronic kidney disease (CKD) in the UK at the ERA-EDTA 2020 Congress. The study aims to compare and validate two different approaches to estimating the burden of CKD in the UK, and to estimate how this is predicted to change by […]